![](https://news.europawire.eu/wp-content/uploads/2023/03/sanofi-144x144.jpg)
(IN BRIEF) In the Phase 3 IsKia trial presented at the American Society of Hematology (ASH) Annual Meeting, Sarclisa® (isatuximab) combined with carfilzomib, lenalidomide, and dexamethasone (KRd) demonstrated a significant improvement in achieving minimal residual disease (MRD) negativity among newly … Read the full press release